Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Glioblastoma × tivozanib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Colorectal Neoplasms 2 Carcinoma, Renal Cell 2 Triple Negative Breast Neoplasms 1 Solid Tumors 1 Sarcoma 1 Recurrence 1 Prostatic Neoplasms 1 Neoplasms 1 Neoplasm Metastasis 1 Liver Neoplasms 1 Glioblastoma 1 Gastrointestinal Neoplasms 1 Fallopian Tube Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Breast Neoplasms 1 Advanced Adult Hepatocellular Carcinoma 1

Interventions

Temozolomide 104 Bevacizumab 64 Radiotherapy 45 Radiation 21 Erlotinib Hydrochloride 12 pembrolizumab 10 Magnetic Resonance Spectroscopy 10 Lomustine 10 Vorinostat 9 Irinotecan 9 Nivolumab 8 Surgical Procedures, Operative 7 Radiotherapy, Intensity-Modulated 7 Immunoglobulin G 7 Disulfides 7 Sorafenib 6 Radiotherapy, Conformal 6 Radiosurgery 6 Drug Therapy 6 Carmustine 6 antineoplaston AS 2-1 5 antineoplaston A10 5 Granulocyte-Macrophage Colony-Stimulating Factor 5 Everolimus 5 veledimex 4 selinexor 4 sargramostim 4 cediranib 4 Dasatinib 4 Cilengitide 4

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT01846871 2019-01-08

Tivozanib for Recurrent Glioblastoma

Massachusetts General Hospital

Phase 2 Completed

10 enrolled 13 charts

Glioblastoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡